WuXi invests $240m in Irish CDMO operations

摘要

WuXi Biologics' subsidiary WuXi Vaccines is to invest US$240 million and build a new vaccine manufacturing facility in Ireland. This investment follows the 20-year manufacturing Letter of Intent (LOI) signed by WuXi Vaccines earlier this year. The new site is set to include drug substance manufacturing (MFG15), drug product manufacturing (DP5), and Quality Control labs (QC). The new facility, subject to planning approval, will be located within the WuXi's Campus adjacent to the "Factory of the Future" biologics drug substance manufacturing site scheduled for commercial manufacturing in 2021.